Phase II Study of Sequential Administration of Doxorubicin, Paclitaxel, and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer
- Determine the response rate and duration of response in patients with primary stage III
or IV or recurrent endometrial cancer treated with sequential doxorubicin, paclitaxel,
OUTLINE: Patients receive sequential chemotherapy comprised of doxorubicin IV once every 2
weeks for 3 courses, followed by paclitaxel IV over 1 hour once weekly for 9 courses, and
then carboplatin IV once every 3 weeks for 3 courses in the absence of disease progression
or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 18-46 patients will be accrued for this study.
Primary Purpose: Treatment
Paul Sabbatini, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|